Kaplan-Meier plot of time to sputum culture conversion, by HIV-status.

<p>Kaplan-Meier plot of time to sputum culture conversion, by HIV-status.</p

Baseline characteristics by HIV status.

<p>IQR: interquartile range; MDR-TB: multidrug-resistant tuberculosis; ART: antiretroviral therapy;</p><p>BMI: body mass index.</p

Outcomes according to study group.

<p>Groups: ____ No OI; …. TB; –– Other OIs.</p

Selected baseline characteristics by study groups.

<p>^a TB = tuberculosis; PTB = pulmonary tuberculosis; ETB = extrapulmonary tuberculosis.</p><p>^b p-values for categorical variables were obtained with the use of the chi-square test, while ANOVA test was used for continuous variables.</p><p>^c ZDV = zidovudine; 3TC = lamivudine; EFV = efavirenz; DDI = didanosine; TDF = tenofovir; FTC = emtricitabine.</p

ACTG A5175/Pearls trial – Survival probability estimate from randomization to treatment failure by pill count non-adherence (solid line = did not miss any pills; dashed line = missed any pills).

<p>ACTG A5175/Pearls trial – Survival probability estimate from randomization to treatment failure by pill count non-adherence (solid line  =  did not miss any pills; dashed line  =  missed any pills).</p

Risk Factors of Time to Treatment Failure.

1<p>All adjusted models include treatment condition.</p><p>Table Legend:</p><p>QOL_health: general health perceptions.</p><p>QOL_mental: mental health.</p

Baseline Participant Characteristics.

<p>Table Legend:</p><p>QOL_health: general health perceptions.</p><p>QOL_mental: mental health.</p><p>Treatment: Once daily protease inhibitor + nucleoside reverse transcriptase inhibitors: atazanavir + didanosine-EC and emtricitabine.</p><p>Treatment: Once daily non-nucleoside reverse transcriptase inhibitor + nucleoside reverse transcriptase inhibitors: efavirenz + co-formulated emtricitabine-tenofovir-DF.</p><p>Standard of care: efavirenz plus co-formulated lamivudine-zidovudine.</p